This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Conference 2024 - Rare Disease Innovation & Partnership Summit
March 18-21, 2024
Philadelphia Marriott DowntownPhiladelphia, PA

Jennifer McNary
Co-Founder at Canary Advisors

Profile

Jenn McNary is a trusted voice in the rare disease community, as a mother, public speaker and fierce advocate. Her work in the rare disease space as a thought leader earned her the Ryan’s Quest Ryan’s Hero award in 2013, and the prestigious 2017 Meyer- Whalley instrument of change award. Formerly as the director of outreach and advocacy at a Massachusetts based non-profit foundation, she was responsible for the organization of the largest FDA advisory committee hearing in history, with over 1000 duchenne advocates, families, clinicians and researchers in attendance. There are currently only three drugs approved for Duchenne, Exondys51, Vyondys53 and Emflaza, though in various roles, Jenn was involved in the approval process for all three. Jenn has unique experience in the drug development field, as a parent of children enrolled in the clinical trials, an advocate engaging with the regulators and as a patient engagement professional in the life sciences.

Currently, Jenn is the Co-Founder and Principal of Canary Advisors, a boutique patient advocacy consulting firm with a focus on regulatory and access patient engagement. Her other activities include serving as the Founder of One Rare, a non-profit formed to meet the needs of young adults with rare and chronic conditions and raising her children in Massachusetts.

Agenda Sessions

  • Strengthening Relationships—Putting the Patient in the Driver’s Seat

    2:30pm